SynthesisFrontiers in oral health2025
Assessment of proteomic salivary biomarkers for diagnosis of early childhood caries: a systematic review.
Synthesis in Frontiers in oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AQP3 as a potential biomarker for caries.BMC oral health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe early childhood caries (s-ECC) remains a highly prevalent condition among children worldwide, posing a considerable burden in both developed and developing regions. This systematic review seeks to comprehensively identify, synthesize, and critically evaluate available evidence on salivary proteomic and peptidomic biomarkers that may aid in the diagnosis or risk assessment of ECC. Aim and objectives: This study aims to evaluate any difference in the level of proteomic salivary biomarkers in children with and without ECC. Methods: A comprehensive search was conducted across four major electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE via PubMed, Scopus, and Google Scholar. From an initial yield of 1,253 records, 11 studies fulfilled the eligibility criteria and were included for data extraction. The risk of bias for the included studies was assessed using the QUADAS-2 tool for the Quality Assessment of Diagnostic Accuracy Studies. Results: Of the 11 studies included, quality appraisal using the QUADAS-2 indicated that 3 out of 11 studies had low risk in all domains, while the remaining studies had unclear or high-risk domains. Conclusion: The pooled evidence suggests that salivary biomarkers have significant potential for detecting ECC. Utilizing salivary diagnostics may enhance the prevention of new carious lesions. Future clinical trials with robust methodologies are recommended to generate further conclusive evidence. Clinical significance: Salivary proteomic biomarkers, including MS protein, mucins, amylase, glycoproteins, proline, and glycine, may provide additional value in the early diagnosis of ECC in pediatric populations. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023468566, PROSPERO CRD42023468566.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.